Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CAR-T anti-cancer therapeutics - Helix BioPharma

Next Previous
Drug Profile

Research programme: CAR-T anti-cancer therapeutics - Helix BioPharma

Alternative Names: Anti-CEACAM6 CAR-T cell therapy - Helix BioPharma; Anti-VEGFR2 CAR-T cell therapy - Helix BioPharma; Bispecific CAR-T cell therapy - Helix BioPharma; Chimeric Antigen Receptor-based cell therapies - Helix BioPharma; Tumour defence attackers - Helix BioPharma

Latest Information Update: 28 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helix BioPharma
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Apr 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in Canada (Parenteral)
  • 28 Mar 2021 No recent reports of development identified for preclinical development in Solid-tumours in Canada (Parenteral)
  • 04 Jan 2018 Helix BioPharma and ProMab Biotechnologies finalised a binding letter of intent to co-develop CAR-T cell therapy for Haematological malignancies and Solid tumours
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top